Ignite Creation Date:
2024-05-06 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03531931
Status:
UNKNOWN
Last Update Posted:
2018-05-22
First Post:
2018-05-09
Brief Title:
Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer a Single-arm Exploratory Clinical Pilot Trial
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
The First Affiliated Hospital of Xiamen University
Study Overview
Official Title:
Single-arm Exploratory Clinical Study on the Second-line Treatment of Advanced Gastric Cancer With Apatinib Mesylate Plus Capecitabine
Status:
UNKNOWN
Status Verified Date:
2018-05
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gastric cancer is the one of the leading cause of cancer death in the worldwide Gastric cancer originates from the most superficial mucosal epithelial cells of the stomach wall which can occur in various parts of the stomach and can invade different depths and breadth of the gastric wall Without chemotherapy treatment the GC patients Median Survival Time MST lasts only 3-4 months Although treated with multi-chemotherapy MST has been improved the drugs show strong toxicities in the patients Thus the more accurate lower toxicity targeted antitumor drugs are put into second-line treatment program for advanced gastric cancer
Apatinib a novel targeted inhibitor of VEGF receptor 2 VEGFR2 shows significant antitumor activity in the patients with GC The purpose of this study is to determine whether apatinib plus capecitatine can improve progression free survival in patients with advanced gastric cancer
Apatinib a novel targeted inhibitor of VEGF receptor 2 VEGFR2 shows significant antitumor activity in the patients with GC The purpose of this study is to determine whether apatinib plus capecitatine can improve progression free survival in patients with advanced gastric cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None